Want to see KR:326030 full AI Analyst Report?
SK Biopharmaceuticals Co., Ltd. (326030) Income Statement
SK Biopharmaceuticals Co., Ltd. Income Statement
Last quarter (Q2 2026), SK Biopharmaceuticals Co., Ltd.'s total revenue was $247.37B, an increase of 40.33% from the same quarter last year. In Q2, SK Biopharmaceuticals Co., Ltd.'s net income was $85.06B. See SK Biopharmaceuticals Co., Ltd.’s key income statements, including revenue, expenses, profit, and income.
| Income Statement | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| $ 706.74B | $ 547.60B | $ 354.89B | $ 246.18B | $ 418.64B | |
| $ 651.67B | $ 504.50B | $ 320.81B | $ 208.41B | $ 396.31B | |
| $ 447.73B | $ 408.16B | $ 358.33B | $ 339.49B | $ 301.35B | |
| Depreciation and Amortization | $ 16.95B | $ 17.43B | $ 15.32B | $ 12.98B | $ 11.64B |
| $ 220.89B | $ 100.71B | $ -8.73B | $ -125.77B | $ 167.68B | |
| $ 203.94B | $ 96.34B | $ -20.63B | $ -131.08B | $ 94.96B | |
| $ -53.05B | $ -23.74B | $ -23.23B | $ -11.39B | $ -23.68B | |
| $ 150.88B | $ 72.60B | $ -43.86B | $ -142.47B | $ 71.28B | |
| $ 266.95B | $ 240.74B | $ -32.88B | $ -139.43B | $ 64.85B | |
| Per Share Metrics | |||||
| Basic EPS | $ 3408.75 | $ 3066.97 | $ -419.89 | $ -1780.43 | $ 828.03 |
| Diluted EPS | $ 3408.75 | $ 3066.97 | $ -419.89 | $ -1780.43 | $ 828.03 |
| Weighted Average Shares Outstanding | 78.31M | 78.31M | 78.31M | 78.31M | 78.31M |
| Weighted Average Shares Outstanding (Diluted) | 78.31M | 78.31M | 78.31M | 78.31M | 78.31M |
Currency in KRW
